Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
- DOI
- 10.3389/fphar.2022.1063178
- Published
- 2023-03-03
- Container
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2022.1063178,
title = {Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab},
author = {Maciej Niewada and Tomasz Macioch and Magdalena Konarska and Aneta Mela and Adam Goszczyński and Bogusława Przekopińska and Karolina Rajkiewicz and Piotr Wysocki and Maciej Krzakowski},
year = {2023},
journal = {Frontiers in Pharmacology},
doi = {10.3389/fphar.2022.1063178},
url = {https://doi.org/10.3389/fphar.2022.1063178}
}RIS
TY - JOUR TI - Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab AU - Maciej Niewada AU - Tomasz Macioch AU - Magdalena Konarska AU - Aneta Mela AU - Adam Goszczyński AU - Bogusława Przekopińska AU - Karolina Rajkiewicz AU - Piotr Wysocki AU - Maciej Krzakowski PY - 2023 JO - Frontiers in Pharmacology DO - 10.3389/fphar.2022.1063178 UR - https://doi.org/10.3389/fphar.2022.1063178 ER -
APA
Niewada, M., Macioch, T., Konarska, M., Mela, A., Goszczyński, A., Przekopińska, B., Rajkiewicz, K., Wysocki, P., & Krzakowski, M. (2023). Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.1063178
Source records
- crossref · retrieved 2026-09-25T04:08:57.932Z